LLY's Weight-Loss Drugs: 66% of Revenue and Growing
💡 Key Takeaway
Eli Lilly's weight-loss and diabetes franchise now accounts for nearly two-thirds of revenue, with accelerating growth and a new pill expanding the market, but concentration risk remains.
What Happened: Weight-Loss Drugs Dominate Lilly's Q1
Eli Lilly reported first-quarter 2026 results showing Mounjaro and Zepbound generated a combined $12.8 billion in revenue, representing nearly two-thirds of the company's $19.8 billion total revenue. Mounjaro, for type 2 diabetes, saw revenue jump 125% year over year to $8.7 billion, while Zepbound, for weight loss, grew 80% to $4.2 billion.
The franchise's momentum is accelerating. Combined revenue more than doubled from $6.2 billion in Q1 2025 to $12.8 billion in Q1 2026. For full-year 2025, the pair brought in $36.5 billion, over half of Lilly's $65.2 billion revenue.
Total Q1 revenue rose 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decline in realized prices. Earnings per share soared 170% to $8.26, and adjusted EPS rose 156% to $8.55.
Management raised full-year 2026 revenue guidance to $82-$85 billion, up $2 billion from prior forecast, and lifted adjusted EPS guidance by $2. The new revenue range implies about 28% growth at the midpoint.
In April, the FDA approved Foundayo, Lilly's once-daily GLP-1 pill for weight loss, with self-pay pricing starting at $149 per month. The pill can be taken anytime without food or water restrictions, potentially expanding the market beyond injection users.
Why It Matters: Concentration Risk vs. Growth Opportunity
The weight-loss franchise is now the overwhelming driver of Lilly's business, accounting for nearly two-thirds of revenue. This concentration means the stock's performance is tightly tied to the success of tirzepatide (Mounjaro/Zepbound) and now Foundayo. Any competitive threat, regulatory setback, or pricing pressure could significantly impact the stock.
On the positive side, the growth is extraordinary. Mounjaro's revenue acceleration from 99% in FY2025 to 125% in Q1 2026 shows no signs of slowing. The new pill Foundayo opens a larger addressable market, especially among patients who prefer oral over injectable medications.
Pricing pressure is a key risk. Realized prices fell 13% in Q1, including cash-pay reductions for Zepbound. So far, volume growth has more than compensated, but if volume growth decelerates, the impact on revenue and margins could be severe.
At $1,184 per share, Lilly trades at about 33 times the midpoint of adjusted EPS guidance. That's a premium multiple, but it's attached to a company guiding for 28% revenue growth. Investors are paying up for a high-growth story, but they must accept the concentration risk.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
Lilly's weight-loss franchise is a powerful growth engine, but investors must monitor pricing and competition closely.
The 28% revenue growth guidance and new pill Foundayo provide a strong runway. However, the 13% price decline and concentration risk warrant caution. The premium valuation is justified as long as growth continues, but any slowdown could trigger a re-rating.
What This Means for Me
